| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/08830738030180100801 Clinical Variability in Rett SyndromeDepartment of Neurogenetics, Kennedy Krieger Institute, naidu{at}kennedykrieger.org., Departments of Neurology and Pediatrics, The Johns Hopkins School of Medicine
Department of Neurogenetics, Kennedy Krieger Institute, Department of Pediatrics, The Johns Hopkins School of Medicine
Division of Metabolism, Kennedy Krieger Institute
Division of Metabolism, Kennedy Krieger Institute, Department of Pediatrics, The Johns Hopkins School of Medicine
Department of Neurology, Kennedy Krieger Institute, Department of Neuroscience, The Johns Hopkins School of Medicine
Center for Genetic Medicine Children's National Medical Center, Washington, DC
Department of Pediatrics, The Johns Hopkins School of Medicine
Department of Biostatistics The Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD
Department of Neuroscience, Kennedy Krieger Institute, Departments of Neurology and Neuroscience The Johns Hopkins School of Medicine
Division of Neurology and Developmental Medicine Kennedy Krieger Institute, Baltimore,, Departments of Neurology and Pediatrics, The Johns Hopkins School of Medicine The clinical variability of Rett syndrome, associated with mutations in the MECP2 gene, varies from classically symptomatic female patients to asymptomatic female patients, and male patients who have none of the diagnostic features considered pathognomonic of this disease. Multiple factors contribute to this variability. In our studies, mutations closer to the amino-terminus, prior to amino acid 255, led to severe clinical manifestations, such as inability to walk, severe dysphagia, and urinary organic acid abnormalities, compared with mutations toward the carboxyl-terminus. However, we found no correlation between severity and mutation type (missense versus nonsense). Despite the importance of mutation location to clinical severity, the widely varying severity within the same mutation suggests that in females, X-chromosome inactivation or other epigenetic phenomena also have roles in determining severity. We propose that stages 1 and 2 of the disease are a consequence of failed, time-linked, postnatal expression of MeCP2 in cerebellar neurons. This, in association with glutamate N-methyl-D-aspartate receptormediated neuroexcitotoxic injury to the differentiating neurons, results in the transient age-specific autistic-like behavior, motor, and cognitive dysfunction associated with these stages. (J Child Neurol 2003; 18:662-668).
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||


